Business Wire·6 days ago
Inogen Announces the Appointment of Andy Reding as Chief Operating OfficerBEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces the Appointment of Andy Reding as Chief Operating Officer.
Inogen, Inc.(INGN)Earnings, Financials & Key Ratios
INGN•NASDAQ
$6.54
Price updated Jul 7, 2026
AboutInogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.Show more
- Revenue$349M+3.9%
- EBITDA-$10M+55.6%
- Net Income-$23M+36.6%
- EPS (Diluted)-0.85+44.1%
- Gross Margin47.58%+3.2%
- EBITDA Margin-2.74%+57.3%
- Operating Margin-8.66%+31.6%
- Net Margin-6.52%+39.0%
- ROE-12.43%+34.4%
INGN Price & Volume
Inogen, Inc. (INGN) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Challenge Inogen Growth Trajectory
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Decelerating
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:High customer acquisition costs
Key Thesis Takeaways
- Inogen faces a challenging fundamental outlook as its direct-to-consumer sales model struggles to generate consistent profitability, evidenced by persistent operating losses and a deceleration in revenue growth to 3.4% in 2026Q1.
- While the company maintains a healthy liquidity buffer with a current ratio of 3.10, the erosion of equity to $182.9 million and the inability to convert accounting earnings into cash flow remain significant structural concerns.
- Investors should monitor whether the company can achieve operating leverage, as SG&A expenses continue to frequently exceed gross profit, threatening long-term business viability.
Verdict Logic
the company has failed to achieve positive operating income in any of the last ten quarters, with operating losses reaching $8.4 million in 2026Q1.
INGN Growth Metrics
Inogen, Inc. (INGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.17%
5 Years2.48%
3 Years-2.59%
TTM3.39%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM9.41%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM20.87%
Return on Capital
10 Years-4.58%
5 Years-17.62%
3 Years-22.71%
Last Year-13.29%
INGN Recent Earnings
Inogen, Inc. (INGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.30-25.0%
$0.24
Rev
$85M+3.4%
$82M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.26+27.8%
$0.36
Rev
$82M-3.9%
$85M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.20+9.1%
$0.22
Rev
$92M+4.3%
$89M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.15+31.8%
$0.22
Rev
$92M-1.1%
$93M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.30vs $0.24-25.0% | $85Mvs $82M+3.4% |
| Q1 2026 | Feb 24, 2026 | $0.26vs $0.36+27.8% | $82Mvs $85M-3.9% |
| Q4 2025 | Nov 5, 2025 | $0.20vs $0.22+9.1% | $92Mvs $89M+4.3% |
| Q3 2025 | Aug 7, 2025 | $0.15vs $0.22+31.8% | $92Mvs $93M-1.1% |
Based on last 12 quarters of dataView full earnings history →
Latest INGN News
Recent stock market news and headlines for Inogen, Inc. (INGN)
Zacks Investment Research·Jun 25, 2026
Here's Why You Should Retain Inogen Stock in Your Portfolio for NowINGN's POC strength, expanding respiratory portfolio and international momentum support growth, though U.S. revenue pressure remains a key risk.
Peers Comparison
Key metrics vs top competitors for Inogen, Inc. (INGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.54 | $177.07M | -7.69 | 3.86% | -6.52% | -12.43% | — | |
| $103.41 | $6.73B | 30.33 | 0.5% | 18.05% | 24.33% | — | |
| $64.33 | $3.26B | 30.06 | 7.03% | 11.51% | 29.92% | — | |
| $38.97 | $813.24M | 15.46 | 3.21% | 4.88% | 13.43% | — | |
| $129.92 | $24.96B | 11.68 | -3.54% | 12.14% | 15.92% | — | |
| $1.53 | $64.62M | -1.15 | 8.01% | -60.09% | -92.94% | — |
Compare INGN vs Peers
Inogen, Inc. (INGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INGN SEC Filings & Documents
Inogen, Inc. (INGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 6, 2026·SEC
Material company update
Mar 30, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when INGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
INGN Frequently Asked Questions
Inogen, Inc. (INGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Inogen, Inc.'s revenue?
Inogen, Inc. (INGN) reported $351.5M in revenue for fiscal year 2025. This represents a 1047% increase from $30.6M in 2011.
How fast is Inogen, Inc. growing?
Inogen, Inc. (INGN) grew revenue by 3.9% over the past year. Growth has been modest.
Is INGN profitable?
Inogen, Inc. (INGN) reported a net loss of $24.9M for fiscal year 2025.
Dividend & Returns
What is INGN's return on equity?
Inogen, Inc. (INGN) has a return on equity (ROE) of -12.4%. Negative ROE indicates the company is unprofitable.
What is Inogen, Inc.'s free cash flow?
Inogen, Inc. (INGN) had negative free cash flow of $10.2M in fiscal year 2025, likely due to heavy capital investments.